FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, namely biopharmaceutics, and may be used for making combined vaccines. For this purpose, the polyvalent combined vaccine contains a type 2 porcine circovirus antigen, and one additional ingredient effective with respect to another organism causing a disease in pigs wherein the type 2 porcine circovirus antigen is a recombinant expressed ORF2 protein of type 2 porcine circovirus specified in: i) a polypeptide containing the sequence SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:9, SEQ ID NO:10 or SEQ ID NO:11, ii) any polypeptide which is homologous to the polypeptide i) at least by 80%, iii) a polypeptide coded by DNA containing the sequence SEQ ID NO:3 or SEQ ID NO:4, iv) any polypeptide which is coded by a polynucleotide which is homologous to the polypeptide iii) at least by 80%, v) any polynucleotide which is coded by the nucleotide sequences SEQ ID NO:3 or SEQ ID NO:4 or any polypeptide coded by the sequences different from SEQ ID NO:3 or SEQ ID NO:4 due to the very 6-20% homology of the sequence, vi) any polypeptide different from SEQ ID NO:5, or any polypeptide different from SEQ ID NO:6, due to the very 6-10% homology of the sequence. What is also presented is a method for reducing a frequency of occurrence or a severity of type 2 porcine circovirus infections.
EFFECT: group of inventions enables producing a high-stable combined PCV2 vaccine.
25 cl, 3 dwg
